2012
DOI: 10.1590/s0365-05962012000400012
| View full text |Cite
|
Sign up to set email alerts
|

Abstract: A focused and commented review on the impact of dermatologic diseases and interventions in the solidary act of donating blood is presented to dermatologists to better advise their patients. This is a review of current Brazilian technical regulations on hemotherapeutic procedures as determined by Ministerial Directive #1353/2011 by the Ministry of Health and current internal regulations of the Hemotherapy Center of Ribeirão Preto, a regional reference center in hemotherapeutic procedures. Criteria for permanent… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
2
2
1

Relationship

3
2

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 11 publications
0
3
0
Order By: Relevance
“…We have previously reported the protective effect of the 5-alpha-reduactase inhibitor, dutasteride, in men with COVID-19, both in hospitalized patients and in an outpatient setting (10)(11)(12). As dutasteride has a half-life of 5 weeks and carries a labeled contraindication for the use in women of childbearing age (18,19), we were keen to explore an antiandrogen that could be applied more broadly. Proxalutamide has been evaluated for 28 days in Phase 1 safety studies for both men and women; furthermore, the half-life is ∼22 h (20).…”
Section: Discussionmentioning
confidence: 99%
“…We have previously reported the protective effect of the 5-alpha-reduactase inhibitor, dutasteride, in men with COVID-19, both in hospitalized patients and in an outpatient setting (10)(11)(12). As dutasteride has a half-life of 5 weeks and carries a labeled contraindication for the use in women of childbearing age (18,19), we were keen to explore an antiandrogen that could be applied more broadly. Proxalutamide has been evaluated for 28 days in Phase 1 safety studies for both men and women; furthermore, the half-life is ∼22 h (20).…”
Section: Discussionmentioning
confidence: 99%
“…We have previously reported the protective effect of the 5-alpha-reduactase inhibitor, dutasteride, in men with COVID-19, both in hospitalized patients and in an outpatient setting. 11,12,18 As dutasteride has a half-life of 5 weeks and carries a labeled contraindication for the use in women of childbearing age, 19 we were keen to explore an antiandrogen that could be applied more broadly. Proxalutamide has been evaluated for 28 days in Phase 1 safety studies for both men and women; furthermore, the pharmacokinetics clearance rate for proxalutamide is 22 hours.…”
Section: Discussionmentioning
confidence: 99%
“…The primary outcome for the study was the percentage of patients hospitalized due to COVID-19. The COVID- 19 17 . In the report it was shown that in Italy the hospitalization rate was as high as 20% among adults above the age of 65 tested positive for SARS-CoV-2.…”
Section: Study Outcomesmentioning
confidence: 99%